Ionis Pharmaceuticals, Inc.
IONS Healthcare Biotechnology
Ionis Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $943.7 million, up 33.8% from fiscal 2024. In the quarter to June 2026, revenue fell 40.7%, EPS fell 188.5%, free cash flow grew 299.3% and total debt rose 116.0%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow IONS
Ionis Pharmaceuticals, Inc. (IONS) EV/Sales
As of 16 October 2026, Ionis Pharmaceuticals, Inc. (IONS) trades at a EV/Sales of 7.8×. Over the past ten years it has ranged from 3.7× (March 2020) to 40.4× (March 2015); the current reading is higher than 41% of that period. That is below the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 12.5× | 108.26% |
| FY2024 | 6.0× | (27.64%) |
| FY2023 | 8.3× | 7.11% |
| FY2022 | 7.7× | 83.57% |
| FY2021 | 4.2× | (55.81%) |
| FY2020 | 9.5× | 58.40% |
| FY2019 | 6.0× | (36.96%) |
| FY2018 | 9.5× | (13.91%) |
| FY2017 | 11.1× | (25.99%) |
| FY2016 | 15.0× | (40.58%) |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 14.7× | 27.02% |
| Mar 2026 | 11.6× | (7.16%) |
| Dec 2025 | 12.5× | 36.13% |
| Sep 2025 | 9.2× | 85.16% |
| 42 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| ABVX Abivax SA Sponsored ADR compare | n/m |
| BLTE Belite Bio, Inc. Sponsored ADR compare | n/m |
| IONS Ionis Pharmaceuticals, Inc. | 7.8× |
| TGTX TG Therapeutics, Inc. compare | 9.8× |
| AXSM Axsome Therapeutics, Inc. compare | 10.2× |
| ARWR Arrowhead Pharmaceuticals, Inc. compare | 10.9× |
| IOVA Iovance Biotherapeutics, Inc. compare | 17.9× |
| PRAX Praxis Precision Medicines, Inc. compare | 735× |
| SYRE Spyre Therapeutics, Inc. compare | 5,336× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)